Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
International Journal of Cancer|December 18, 2021
Ninety-day mortality and clinical outcomes of patients with solid tumours and COVID-19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective studyJose Carlos Tapia, Javier Gavira, Assumpció López, et al.
International Journal of Molecular Sciences|October 27, 2022
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse EventsLeticia Alserawan, Geòrgia Anguera, Carlos Zamora Atenza, et al.
Frontiers in Oncology|October 5, 2020
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade AgentsMariona Riudavets, Joaquin Mosquera, Rosario Garcia-Campelo, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie studyNicolas Epaillard, Jose Carlos Benitez, Teresa Gorria, et al.
JTO Clinical and Research Reports|January 8, 2026
Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief ReportAdele Bonato, Claudia Parisi, Priscilla Cascetta, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2021
Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agentsCarlos Zamora, Mariona Riudavets, Georgia Anguera, et al.
Cancer Immunology, Immunotherapy : CII|January 5, 2022
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agentsCarlos Zamora Atenza, Geòrgia Anguera, Mariona Riudavets Melià, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|February 1, 2025
Clinical and economic impact of the advanced practice nurse in lung cancer patients receiving immunotherapy-based treatments: A quantitative studyJorgina Serra-López, Clara Pujol-Besora, Sergio Martínez-Recio, et al.
Lung Cancer (Amsterdam, Netherlands)|December 26, 2021
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trialMariona Riudavets, Marie Naigeon, Matthieu Texier, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 22, 2021
Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinomaMariona Riudavets, Joaquim Bosch-Barrera, Luís Cabezón-Gutiérrez, et al.
Pageof 3